GlassScriptPhysician profile
Brandi Rhoads
NPI 1396320461
$2,090.27
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $504 · 2023: $38.54 · 2024: $1,042 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.42 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $266.06 | 2024-2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $259.34 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.25 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $142.32 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Gilead Sciences, INC. | $142.19 | 2024 | Epclusa |
| Axsome Therapeutics, INC. | $139.80 | 2024-2025 | Auvelity |
| Insulet Corporation | $110.66 | 2022 | |
| Abbvie INC. | $110.41 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.74 | 2025 | Cobenfy |
| Indivior INC. | $89.07 | 2024-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $73.71 | 2022 | |
| Amgen INC. | $67.92 | 2022 | |
| Esperion Therapeutics, INC. | $60.45 | 2022 | |
| Vanda Pharmaceuticals INC. | $54.59 | 2024 | Fanapt |
| Novartis Pharmaceuticals Corporation | $38.54 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $35.88 | 2022 | |
| Novo Nordisk INC | $35.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.08 | 2022 | |
| Lilly USA, LLC | $31.37 | 2022 | |
| Lundbeck LLC | $15.47 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $13.95 | 2025 | Invega Sustenna |
| Orexo US, INC. | $13.55 | 2025 | Zubsolv |
| Currax Pharmaceuticals LLC | $13.52 | 2022 | |
| Merck Sharp & Dohme LLC | $13.19 | 2022 | |
| Radius Health, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Rhoads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.